Many recent advances in insulin treatment options have focused on dosing convenience. The newest once-weekly insulin products such as insulin icodec (although not currently available in the United States) have demonstrated clinical outcomes similar to once-daily options, but with potentially increased hypoglycemia (1). In a recent American Diabetes Association survey of people with type 1 diabetes (2), >20% of respondents reported having a severe hypoglycemia episode within the past 12 months. Findings from another study (3) suggested that half of all people with type 2 diabetes may be failing to reach their treatment goals with current therapeutic options.
Glucose-responsive insulins are a potential solution to these problems. Glucose-responsive insulins have been in development for nearly 50 years. Are we close to being able to add them to our treatment options? Three recent animal-based studies exploring different delivery mechanisms for glucose-responsive formulations are discussed below....
